SCHEMBL9890800

SCHEMBL9890800

CNC(=O)C(C)c1ccccc1-c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.44
HTT P42858 3/20 0.43
CNR1 P21554 1/20 0.42
PTGS2 P35354 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
FFAR1 O14842 1/20 0.40
MTOR P42345 1/20 0.39
RECQL P46063 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890794 0.86 HTT (0.43) CNR2HTTCNR1MEN1KMT2A
SCHEMBL1072966 0.84 PTGS2 (0.56) HTTPTGS2MEN1KMT2ALMNA
SCHEMBL2391822 0.84 FGFR1 (0.44) HTTPTGS2MEN1KMT2ALMNA
SCHEMBL2393565 0.83 PTGS2 (0.43) HTTPTGS2TUBB4ATUBBTUBA3C
SCHEMBL2391917 0.78 GAA (0.42) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL29519353 0.77 ESR2 (0.42) HTTPTGS2LMNASMN1; SMN2MAPT
SCHEMBL29519480 0.77 ALOX5AP (0.47) LMNASMN1; SMN2MAPTFFAR1RECQL
SCHEMBL13006376 0.77 ALOX5AP (0.47) LMNASMN1; SMN2MAPTFFAR1RECQL
SCHEMBL9890686 0.75 TUBB4A (0.44) HTTKDM4ETUBB4ATUBBTUBA3C
SCHEMBL2389486 0.75 MAOB (0.46) HTTPTGS2TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CNR2 149/4885HTT 3070/4885CNR1 221/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CNR2 149/4885HTT 3070/4885CNR1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.